4.5 Article

Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/S1570-0232(02)00395-1

关键词

doxorubicin; doxorubicinol

资金

  1. NCI NIH HHS [R01 CA52168] Funding Source: Medline
  2. NCRR NIH HHS [M01 RR000070, M01 RR00070] Funding Source: Medline
  3. NIAID NIH HHS [R01 AI052168] Funding Source: Medline

向作者/读者索取更多资源

A high-performance liquid chromatographic method was developed for the quantification of doxorubicin derived from PEGrylated liposomal doxorubicin (Doxil) and its major metabolite in human plasma. This method utilizes Triton X-100 to disperse the liposome, followed by a protein precipitation step with 5-sulfosalicylic acid. Analytes in the resultant supernatant are separated on a Discovery RP amide C-16 column (250 x 3 min I.D., 5 mum) using an isocratic elution with a mobile phase consisting of 0.05 M sodium acetate (pH 4.0) and acetonitrile (72:28). The retention times for doxorubicin and the internal standard daunorubicin were 4.8 and 10.1 min, respectively. The column eluate was monitored by UV-visible detection at 487 mn. The determination of doxorubicin was found to be linear in the range of 1.0 ng/mL to 25 mug/mL, with intra-day and inter-day coefficients of variation and percent error less than or equal to10%. The recovery of doxorubicin from plasma was >69.3%, with a liposomal dispersion efficiency of >95.7%. Our analytical method for free and PEGylated doxorubicin in human plasma is rapid, avoids organic extractions, and maintains sensitivity for the parent compound and its major metabolite, doxorubicinol. (C) 2002 Elsevier Science B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据